News

These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for the development of human cancer

In this role, Mr Koslow will lead the development and execution of Q Pharma’s sales and marketing efforts, as well as expand the company’s strategic relationships. Q Pharma

The round was led by DE Shaw Venture Capital of Cupertino, California, and included existing investors the Canadian Medical Discoveries Fund, managed by JovInvestment Management, part of Jovian

The study is the second pivotal Phase III clinical trial for Ophena, a new selective estrogen receptor modulator for the treatment of postmenopausal vaginal syndrome (PVS), a common

In conjunction with Mr Patel’s appointment, Synageva has opened new corporate headquarters outside of Boston in Waltham, Massachusetts. The company maintains research and production operations in the greater

The acquisition of GeneSystems, with its patented approach to rapid microbiological detection equipment and disposables, expands Pall’s total fluid management capabilities in the $1 billion biopharmaceuticals process monitoring

This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. In the Phase

The company plans to begin a Phase I clinical trial in early 2010. Azaya is licensing the technology, now known as Azaya Liposomal Encapsulated Radiation Therapy (ALERT), from

The European Commission approval is based on data from three multicenter, randomized, placebo-controlled clinical trials that evaluated the efficacy and safety of Vimpat adjunctive treatment in over 1,300